- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion, Trial completion date, Trial primary completion date: A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Mar 12, 2024 P=N/A, N=10, Completed, Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Mar 2024 | Trial primary completion date: Nov 2024 --> Mar 2024
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jun 7, 2022 P=N/A, N=10, Active, not recruiting, Clinical trial information: NCT04161781. Recruiting --> Active, not recruiting | N=35 --> 10 | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Assessing PD-L1 without a biopsy and through PD-L1 PET imaging with 18F-BMS-986229. (Available On Demand; 233) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1638; P2 The signal of PD-L1 positivity by PET imaging with 18F-BMS-986229 at baseline appears associated with early efficacy from nivo + ipi in this small cohort and may offer additional information than PD-L1 IHC. The ability to assess PD-L1 on a whole patient level at multiple timepoints on treatment may have future implications in how best to sequence and combine immunotherapies but further study in larger patient cohorts is needed.
|